GGrantIndex
← Leaderboards

Rie Sakai-Bizmark

Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center

$1,565,129
Attributed
$1,565,129
Total exposure
3
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $368.7K · FY201825
$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$1,565,129 · 3

By mechanism

R21$877,116 · 2
K01$688,013 · 1

Top collaborators

No co-investigators on record.

Others in their field

Other Emerging Leaders on “Family

Research focus

FamilyHospitalsNeonatal ScreeningInnovationLifeMortalityEligibility DeterminationCharacteristicsFutureInfant OutcomeCostCongenital Heart DisorderLive BirthMorbidity - Disease RateAdherenceDiagnosisAreaCathetersAffectFaceInterviewInfantBaseNewborn Infant

Grant awards (9)

Suicidal Behavior among Adolescents Experiencing Homelessness in the US during the COVID-19 Pandemic$193,568
R21 · FY2025 · MH · contact PI
Suicidal Behavior among Adolescents Experiencing Homelessness in the US during the COVID-19 Pandemic$259,773
R21 · FY2024 · MH · contact PI
Disparities in the effect of state policy for the newborn screening for critical congenital heart diseases$192,625
R21 · FY2022 · HD · contact PI
Newborn Screening for Critical Congenital Heart Disease in U.S.: Assessment of implementation obstacles and application of cost-effectiveness to gauge if action needed for improved implementation$137,619
K01 · FY2022 · HL · contact PI
Disparities in the effect of state policy for the newborn screening for critical congenital heart diseases$231,150
R21 · FY2021 · HD · contact PI
Newborn Screening for Critical Congenital Heart Disease in U.S.: Assessment of implementation obstacles and application of cost-effectiveness to gauge if action needed for improved implementation$137,537
K01 · FY2021 · HL · contact PI
Newborn Screening for Critical Congenital Heart Disease in U.S.: Assessment of implementation obstacles and application of cost-effectiveness to gauge if action needed for improved implementation$137,619
K01 · FY2020 · HL · contact PI
Newborn Screening for Critical Congenital Heart Disease in U.S.: Assessment of implementation obstacles and application of cost-effectiveness to gauge if action needed for improved implementation$137,619
K01 · FY2019 · HL · contact PI
Newborn Screening for Critical Congenital Heart Disease in U.S.: Assessment of implementation obstacles and application of cost-effectiveness to gauge if action needed for improved implementation$137,619
K01 · FY2018 · HL · contact PI